학술논문
Targeting alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial.
Document Type
journal article
Author
Source
Future Oncology; Aug2022, Vol. 18 Issue 21, p2599-2614, 16p
Subject
Language
ISSN
14796694
Abstract
Copyright of Future Oncology is the property of Future Medicine Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)